Atomoxetine is a selective norepinephrine reuptake inhibitor offering a non-stimulant option for ADHD management, particularly valued where stimulant abuse potential is a concern. Simson Pharma's Atomoxetine reference standard and impurities support compendial testing for this established non-stimulant therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Atomoxetine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.